Similarly, a large retrospective cohort analysis by Liu et al. using the TriNetX database, which included over 160000 matched patients aged ≥65 with T2DM, found that SGLT2 inhibitor use was associated with a significantly lower risk of new-onset dementia compared to DPP-4 inhibitors (HR: 0.54; 95% CI: 0.51-0.57) [7]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.